Compare Sanofi SA (SNY) vs Millicom International Cellular S.A. Common Stock (TIGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Millicom International Cellular S.A. Common Stock — how do they compare? Sanofi SA trades at $40.51 (market cap $94.58B), while Millicom International Cellular S.A. Common Stock trades at $81.05 (market cap $13.34B). The key difference: Sanofi SA is far larger — about 7.1× Millicom International Cellular S.A. Common Stock's market cap, and Sanofi SA pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Millicom International Cellular S.A. Common Stock for 0 Days on average.
| SNY | TIGO | |
|---|---|---|
Market Cap | $94.58B | $13.34B |
Volume | 3,988,460 | 1,586,684 |
Sector | Health | Media |
52-Week High | $52.34 | $104.31 |
52-Week Low | $39.12 | $45.81 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $113.80B | $24.38B |
Dividend Yield | 6.18% | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $39.12, down 1.56% with a bearish technical signal despite recent earnings beats. The company shows solid fundamentals with $46.72B revenue, 16.72% net margin, and reasonable valuation (P/E 21.71). Recent expansion of the Regeneron immunology alliance worth up to $8B signals growth potential beyond Dupixent, though 2026 forecasts indicate profit margin compression to 8.09%.
SNY presents a mixed outlook with strong current execution offset by future margin pressures. The bullish analyst consensus (44% Buy) and expanding immunology pipeline provide upside catalysts, while patent expirations and competitive threats pose medium-term risks. Cash flow volatility and debt levels require monitoring for long-term investors.
TIGO trades at $79.54, down 0.92% on the day, with a neutral technical signal and key support at $79. The company reported strong 2025 results with $5.82B revenue and $1.32B net income, but 2026 earnings have missed expectations in two of the last three quarters. Recent news highlights its addition to Zacks' Strong Buy list and a consistent $0.75 quarterly dividend.
The stock offers a 12.9% upside to the consensus price target of $89.78, supported by solid profitability and cash flow, but faces risks from earnings volatility and high debt. Analyst sentiment is mixed with a Hold consensus, suggesting cautious optimism amid integration challenges from recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Millicom International Cellular S.A. Common Stock
Millicom International Cellular S.A. operates telecommunications and digital services under the Tigo brand across Latin America, providing mobile, fiber broadband, and pay-TV services. The company also offers mobile financial services through its Tigo Money business.
Read more on TIGO →
